> Detailanzeige

Schuck, Robert N.; Woodcock, Janet; Zineh, Issam; Stein, Peter; Jarow, Jonathan; Temple, Robert; Permutt, Thomas; LaVange, Lisa; Beaver, Julia A.; Charlab, Rosane; Blumenthal, Gideon M.; Dorff, Sarah E.; Leptak, Christopher; Lemery, Steven; Rogers, Hobart; Chowdhury, Badrul; Litwack, E. David; Pacanowski, Michael

Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease
  • Beteiligte: Schuck, Robert N.; Woodcock, Janet; Zineh, Issam; Stein, Peter; Jarow, Jonathan; Temple, Robert; Permutt, Thomas; LaVange, Lisa; Beaver, Julia A.; Charlab, Rosane; Blumenthal, Gideon M.; Dorff, Sarah E.; Leptak, Christopher; Lemery, Steven; Rogers, Hobart; Chowdhury, Badrul; Litwack, E. David; Pacanowski, Michael
  • Erschienen: Wiley, 2018
  • Erschienen in: Clinical Pharmacology & Therapeutics, 104 (2018) 2, Seite 282-289
  • Sprache: Englisch
  • DOI: 10.1002/cpt.1041
  • ISSN: 0009-9236; 1532-6535
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Advances in our understanding of the molecular underpinnings of disease have spurred the development of targeted therapies and the use of precision medicine approaches in patient care. While targeted therapies have improved our capability to provide effective treatments to patients, they also present additional challenges to drug development and benefit–risk assessment such as identifying the subset(s) of patients likely to respond to the drug, assessing heterogeneity in response across molecular subsets of a disease, and developing diagnostic tests to identify patients for treatment. These challenges are particularly difficult to address when targeted therapies are developed to treat diseases with multiple molecular subtypes that occur at low frequencies. To help address these challenges, the US Food and Drug Administration recently published a draft guidance entitled “Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease.” Here we provide additional information on specific aspects of targeted therapy development in diseases with low‐frequency molecular subsets.